2024
Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review
Nasioudis D, Pashankar F. Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review. International Journal Of Gynecological Cancer 2024, 34: 1454-1460. PMID: 38991656, DOI: 10.1136/ijgc-2023-005052.Peer-Reviewed Original ResearchMalignant ovarian germ cell tumorsOvarian germ cell tumorsGerm cell tumorsCell tumorsHigh-dose chemotherapy protocolsPlatinum-resistant diseasePlatinum-sensitive diseaseSecondary cytoreductive surgeryPlatinum-based chemotherapyStandard dose chemotherapyCytoreductive surgeryDose chemotherapyTumor relapseOptimal resectionChemotherapy protocolsGenomic alterationsSpecialized centersTumorTherapeutic approachesSensitive diseasePatientsChemotherapyNarrative reviewOptimal timingDiseaseConsensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective
Pashankar F, Murray M, Gell J, MacDonald N, Shamash J, Billmire D, Klosterkemper L, Olson T, Hirsch M, Lockley M, Stoneham S, Frazier A. Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective. EClinicalMedicine 2024, 69: 102453. PMID: 38544795, PMCID: PMC10965411, DOI: 10.1016/j.eclinm.2024.102453.Peer-Reviewed Original ResearchOvarian immature teratomaImmature teratomaElevated serum alpha-fetoproteinSurgery-only approachSerum alpha-fetoproteinOvarian ITStage IAAdjuvant chemotherapyRare neoplasmsOvarian cancerAdult patientsAlpha-fetoproteinLack of published dataPathologic interpretationPatient managementLow-gradeGrade 1Multiple subspecialtiesPatientsTeratomaYoung femalesAdult practiceNational advisory panelPaediatric teamGCTNormal Erythroid Precursors in Diamond-Blackfan Anemia: A Rare Case Highlighting Challenges That Remain
Prior D, Sowa A, Pashankar F. Normal Erythroid Precursors in Diamond-Blackfan Anemia: A Rare Case Highlighting Challenges That Remain. Journal Of Pediatric Hematology/Oncology 2024, 46: e195-e198. PMID: 38277626, DOI: 10.1097/mph.0000000000002820.Peer-Reviewed Original ResearchConceptsDiamond-Blackfan anemiaDiamond-BlackfanDiagnosis of Diamond-Blackfan anemiaInherited bone marrow failure syndromeBone marrow failure syndromesMarrow failure syndromesDiagnostically challenging casesFailure syndromeAtypical manifestationsSpontaneous remissionRare caseErythroid precursorsChallenging casesGenetic etiologyPhenotypic manifestationsAnemiaPatientsRemissionRelapseHypoplasiaSyndromeEtiologyDiagnosis
2021
Prevalence and risk factors of cognitive impairment in children with sickle cell disease in Egypt
Youssry I, ElGhamrawy M, Seif H, Balsamo L, Pashankar F, Mahrous M, Salama N. Prevalence and risk factors of cognitive impairment in children with sickle cell disease in Egypt. International Journal Of Hematology 2021, 115: 399-405. PMID: 34792734, DOI: 10.1007/s12185-021-03260-1.Peer-Reviewed Original ResearchConceptsSickle cell diseaseHigh lactate dehydrogenaseCell diseaseCognitive impairmentRisk factorsLactate dehydrogenaseCairo University Children's HospitalOlder ageSickle cell disease patientsUniversity Children's HospitalPossible risk factorsMagnetic resonance angiographyMagnetic resonance imagingHydroxyurea therapyTranscranial DopplerChildren's HospitalDisease patientsUnivariate analysisEarly initiationPatientsResonance angiographyImpaired cognitionResonance imagingIntelligence quotient (IQ) testDiseasePulmonary Metastasis of Low-risk Perinatal Neuroblastoma After Resection: Implications for Surveillance
Ullrich SJ, Worhunsky D, Rodwin R, Pashankar F, Christison-Lagay E, Ozgediz D. Pulmonary Metastasis of Low-risk Perinatal Neuroblastoma After Resection: Implications for Surveillance. Journal Of Pediatric Hematology/Oncology 2021, 43: e184-e186. PMID: 31815890, DOI: 10.1097/mph.0000000000001693.Peer-Reviewed Case Reports and Technical Notes
2019
3.22 EMOTION REGULATION IN PEDIATRIC SICKLE CELL PATIENTS: ASSOCIATIONS WITH SYMPTOMS OF DEPRESSION, ANXIETY, AND PAIN INTERFERENCE
Miller M, Bailey C, Pashankar F, Balsamo L. 3.22 EMOTION REGULATION IN PEDIATRIC SICKLE CELL PATIENTS: ASSOCIATIONS WITH SYMPTOMS OF DEPRESSION, ANXIETY, AND PAIN INTERFERENCE. Journal Of The American Academy Of Child & Adolescent Psychiatry 2019, 58: s202. DOI: 10.1016/j.jaac.2019.08.185.Peer-Reviewed Original ResearchTreatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study.
Rodriguez-Galindo C, Krailo MD, Krasin MJ, Huang L, McCarville MB, Hicks J, Pashankar F, Pappo AS. Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study. Journal Of Clinical Oncology 2019, 37: 3369-3376. PMID: 31553639, PMCID: PMC6920031, DOI: 10.1200/jco.19.01276.Peer-Reviewed Original ResearchConceptsEvent-free survivalChildhood nasopharyngeal carcinomaInduction chemotherapyConcurrent chemoradiotherapyStage IIBNasopharyngeal carcinomaCycles of ICCancer stage IIBPediatric-specific studiesCycles of cisplatinOverall survival estimatesAmerican Joint CommitteeDoses of cisplatinCumulative incidence estimatesRadiation dose reductionAdult regimensStable diseaseAdvanced diseasePartial responseMedian ageExcellent outcomesIncidence estimatesDose reductionPatientsJoint Committeeα‐Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium
O’Neill A, Xia C, Krailo MD, Shaikh F, Pashankar FD, Billmire DF, Olson TA, Amatruda JF, Villaluna D, Huang L, Malogolowkin M, Rodriguez‐Galindo C, Frazier AL. α‐Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium. Cancer 2019, 125: 3649-3656. PMID: 31355926, DOI: 10.1002/cncr.32363.Peer-Reviewed Original ResearchConceptsGerm cell tumorsChildren's Oncology GroupCell tumorsAFP declineCumulative incidenceOncology GroupOverall survivalPediatric patientsThree-year overall survivalFuture clinical trial designTumor marker declineStart of chemotherapyPredictors of outcomeRecognition of patientsClinical trial designYears of ageAdult patientsPoor prognosisSerum AFPMarker declineStratified analysisHigh riskTrial designPatientsEarly intensificationSustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma
Natarajan E, Auerbach C, Cheron R, Pashankar F. Sustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma. Journal Of Pediatric Hematology/Oncology 2019, 42: e659-e661. PMID: 31259823, DOI: 10.1097/mph.0000000000001544.Peer-Reviewed Original ResearchConceptsRecurrent hepatoblastomaIfosfamide/carboplatin/etoposide chemotherapyLong-term disease-free survivalCarboplatin/etoposide chemotherapyDisease-free survivalLimited treatment optionsAdjuvant chemotherapySecond relapseEtoposide chemotherapyFirst relapseMultiple relapsesSurgical resectionPoor prognosisTreatment optionsMetastatic hepatoblastomaHepatoblastomaRelapseChemotherapyIrinotecanChildrenRemissionResectionPostresectionPatientsPrognosisGrowing Teratoma Syndrome After Chemotherapy For Ovarian Immature Teratoma
Imran H, Siddiqui AH, Wilson F, Pashankar F. Growing Teratoma Syndrome After Chemotherapy For Ovarian Immature Teratoma. Journal Of Pediatric Hematology/Oncology 2019, 42: e630-e633. PMID: 31205224, DOI: 10.1097/mph.0000000000001525.Peer-Reviewed Original ResearchConceptsOvarian immature teratomaRecurrent immature teratomaImmature teratomaTeratoma syndromePediatric patientsMainstay of treatmentPostoperative chemotherapyGynecologic oncologistsPediatric oncologistsAdult providersChemotherapyPatientsOncologistsSyndromeTeratomaAdultsTreatmentSurgeryRecurrenceManagementMainstayOutcomes of adolescent males with extracranial malignant germ cell tumors compared with children and young adults: A report from the Malignant Germ Cell Tumors International Consortium (MaGIC) group.
Shaikh F, Stark D, Dang H, Xia C, Krailo M, Stenning S, Pashankar F, Rodriguez-Galindo C, Olson T, Hale J, Depani S, Stoneham S, Nicholson J, Murray M, Amatruda J, Billmire D, Fonseca A, Frazier A. Outcomes of adolescent males with extracranial malignant germ cell tumors compared with children and young adults: A report from the Malignant Germ Cell Tumors International Consortium (MaGIC) group. Journal Of Clinical Oncology 2019, 37: 10022-10022. DOI: 10.1200/jco.2019.37.15_suppl.10022.Peer-Reviewed Original ResearchMalignant germ cell tumorsExtracranial malignant germ cell tumorsEvent-free survivalGerm cell tumorsYoung adultsAdolescent patientsCell tumorsCox proportional hazards analysisIndividual patient databaseCox multivariable analysisPlatinum-based chemotherapyProportional hazards analysisYoung adult patientsPediatric cooperative groupsAdult patientsClinical characteristicsSame regimensMale patientsMultivariable analysisInclusion criteriaPatientsPatient databaseAge groupsAdult groupAdolescent malesAlfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium.
O'Neill A, Xia C, Krailo M, Shaikh F, Pashankar F, Billmire D, Olson T, Amatruda J, Villaluna D, Malogolowkin M, Rodriguez-Galindo C, Frazier A. Alfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium. Journal Of Clinical Oncology 2019, 37: 10036-10036. DOI: 10.1200/jco.2019.37.15_suppl.10036.Peer-Reviewed Original ResearchEvent-free survivalGerm cell tumorsAFP declinePediatric patientsCell tumorsTumor marker declineStart of chemotherapyDays of chemotherapyStandard-risk diseaseYears of ageAdult patientsRisk diseasePoor prognosisSerum AFPMarker declineStratified analysisPatientsChemotherapyTumorsInitial daysDaysDeclinePrognosisDiseaseCarcinomas in the children and young adults: A report form Children’s Oncology Group APEC14B1 study.
Venkatramani R, Piao J, Krailo M, Rodriguez-Galindo C, Pashankar F. Carcinomas in the children and young adults: A report form Children’s Oncology Group APEC14B1 study. Journal Of Clinical Oncology 2019, 37: e21505-e21505. DOI: 10.1200/jco.2019.37.15_suppl.e21505.Peer-Reviewed Original ResearchYoung adultsDistant metastasisThyroid cancerChildren's Oncology Group institutionsPercent of patientsEnrollment of patientsRenal cell carcinomaBiology of carcinomaFemale predominanceLymph nodesMedian ageCell carcinomaColorectal cancerCancer patientsMetastasis statusAdrenocortical cancerEpidemiologic informationNasopharyngeal carcinomaWhite raceOutcome studiesPatientsCarcinomaTissue submissionEligibility screeningAge groups
2018
Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group
Fonseca A, Xia C, Lorenzo AJ, Krailo M, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Billmire DF, Rodriguez-Galindo C, Frazier AL, Shaikh F. Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group. Journal Of Clinical Oncology 2018, 37: 396-402. PMID: 30576269, PMCID: PMC6553816, DOI: 10.1200/jco.18.00790.Peer-Reviewed Original ResearchConceptsMalignant germ cell tumorsTumor marker elevationNongerminomatous malignant germ cell tumorsAbnormal tumor markersGerm cell tumorsMarker elevationTumor markersRelapse surveillanceOncology GroupInitial diagnosisCell tumorsChildren's Oncology GroupDetection of relapseSingle-arm trialNormal tumor markersCase report formsAbnormal imagingCentral reviewMarker levelsPathology reportsRelapsePatientsPhase IIIReport formsComplete dataIs carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
Shah R, Xia C, Krailo M, Amatruda JF, Arul SG, Billmire DF, Brady WE, Covens A, Gershenson DM, Hale JP, Hurteau J, Murray MJ, Nicholson JC, Olson TA, Pashankar F, Rodriguez-Galindo C, Shaikh F, Stark D, Frazier AL, Stoneham S. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults? Gynecologic Oncology 2018, 150: 253-260. PMID: 29884437, DOI: 10.1016/j.ygyno.2018.05.025.Peer-Reviewed Original ResearchConceptsCisplatin-based chemotherapyClinical trial organizationsGerm cell tumorsFive-year event-free survivalMalignant ovarian germ cell tumorsOvarian germ cell tumorsAge groupsCarboplatin-based chemotherapyTreatment-related toxicityEvent-free survivalEligible patientsExcellent OSMetastatic diseaseOverall survivalClinical outcomesFrontline treatmentSurvival outcomesMean agePeak incidenceCell tumorsDysgerminomaChemotherapyPatientsTrials OrganizationCarboplatinComparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium
Frazier AL, Stoneham S, Rodriguez-Galindo C, Dang H, Xia C, Olson TA, Murray MJ, Amatruda JF, Shaikh F, Pashankar F, Billmire D, Krailo M, Stark D, Brougham MFH, Nicholson JC, Hale JP. Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium. European Journal Of Cancer 2018, 98: 30-37. PMID: 29859339, DOI: 10.1016/j.ejca.2018.03.004.Peer-Reviewed Original ResearchConceptsChildren's Oncology GroupEvent-free survivalOncology GroupClinical trialsGerm cell tumor patientsCarboplatin-based regimensCisplatin-based regimensParametric cure modelsLeukemia groupTumor patientsStandard riskChildren's CancerRegimensCancerRiskTrialsGroupCure modelPatientsCarboplatinInternational ConsortiumCisplatinP3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).
Grimison P, Lawrence N, Stockler M, Martin A, Yip S, Wong N, Yeung A, Friedlander M, Mazhar D, Pashankar F, Quinn D, McDermott R, Walker R, Winstanley M, Hanning F, Weickhardt A, Stevanovic A, Davis I, Toner G. P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs). Journal Of Clinical Oncology 2018, 36: tps4596-tps4596. DOI: 10.1200/jco.2018.36.15_suppl.tps4596.Peer-Reviewed Original ResearchTreatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study
Pashankar F, Frazier AL, Krailo M, Xia C, Pappo AS, Malogolowkin M, Olson TA, Rodriguez‐Galindo C. Treatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study. Pediatric Blood & Cancer 2018, 65: e27111. PMID: 29697191, PMCID: PMC6019185, DOI: 10.1002/pbc.27111.Peer-Reviewed Original ResearchConceptsMalignant germ cell tumorsPediatric malignant germ cell tumorsGerm cell tumorsOncology GroupCell tumorsMarker declineRefractory germ cell tumorsHigh-dose chemotherapyPhase II trialChildren's Oncology GroupGroup of patientsLong-term toxicityRECIST responseSalvage therapyStable diseaseTIP regimenII trialRECIST criteriaElevated markersPartial responseProgressive diseaseStandard therapyAdditional administrationTumor markersPatients
2017
Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study
Dicken BJ, Billmire DF, Krailo M, Xia C, Shaikh F, Cullen JW, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Rescorla FJ, Egler RA, Ross JH, Rodriguez‐Galindo C, Frazier AL. Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study. Pediatric Blood & Cancer 2017, 65 PMID: 29286555, PMCID: PMC6219870, DOI: 10.1002/pbc.26913.Peer-Reviewed Original ResearchConceptsOvarian germ cell tumorsMalignant ovarian germ cell tumorsGerm cell tumorsEvent-free survivalNon-GD patientsOverall survivalGonadal dysgenesisMalignant germ cell tumorsAggressive chemotherapy regimenHigh-risk groupNondysgerminomatous tumorsChemotherapy regimenPure dysgerminomaPediatric patientsSac tumorBilateral gonadectomyCell tumorsWorse outcomesEmbryonal carcinomaPatientsStreak ovariesDysgenetic gonadsTumorsY chromosome materialGonadoblastomaImmature Ovarian Teratoma
Faure-Conter C, Pashankar F. Immature Ovarian Teratoma. Journal Of Pediatric Hematology/Oncology 2017, 39: 487-489. PMID: 28859031, DOI: 10.1097/mph.0000000000000950.Peer-Reviewed Original ResearchConceptsOvarian immature teratomaImmature teratomaPure ovarian immature teratomaFIGO stage IARole of chemotherapyImmature ovarian teratomaGrade 1 tumorsStandard of careAdjuvant chemotherapyAdult oncologistsMalignant relapseStage IAPediatric seriesOvarian teratomaPediatric teamAdult womenChemotherapyTumorsTeratomaUrgent needRelapsePatientsSurgeryOncologistsPediatrics